(0)
- Treatment informed by Axumin PET imaging significantly improved event-free-survival for men with recurrent prostate cancer at three and four years -
- Winship Cancer Institute of Emory University s EMPIRE-1 trial is first-of-its-kind randomized patient outcomes study of amino acid PET imaging in influencing a cancer control endpoint -
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, is pleased to share news of the publication of a study from researchers at Winship Cancer Institute of Emory University (Winship) evaluating Axumin (fluciclovine F 18) PET imaging in men with recurrent prostate cancer. The randomized, prospective study showed that Axumin-guided post-prostatectomy radiation therapy increased biochemical event-free survival rates in men with recurrent disease. Among 165 patients whose prostate cancer had returned following surgical removal of their prostate, 75.5% whose t
Dr Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Intrance Medical Systems Establishes U S Operations and Names Patrick Shea Chief Executive Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
(0)
Pharmaceutical industry leader to build organization from ground up with commitment to bringing innovation to the advanced Parkinson s disease community
Company plans to initiate U.S. clinical development of its fixed-dose combination treatment for enteral infusion in advanced Parkinson s disease patients
Intrance Medical Systems, Inc., a subsidiary of Sweden-based Intrance Holdings AB, today announced the company has officially established its U.S. operations with the appointment of Patrick M. Shea as Chief Executive Officer and member of the Board of Directors. Mr. Shea will be responsible for building the company s operational and business structure and initiating the U.S. clinical development program for its fixed-dose combination treatment of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinson s disease patients. The product is currently marketed as Lecigon in the Nordic countries and certain European markets.